Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found — glp1.how · GLP-1 Guides
Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found
If you've lost weight on Zepbound or Wegovy and want off the weekly injection, can a daily pill hold your results? One randomized trial has now tested exactly that. Here's what it found, how much weight people kept, what the switch felt like, and the big question the trial didn't answer.
Updated Sep 20, 2026Evidence-backed
You've lost the weight on a weekly injection. Now the injections are the part you'd like to be done with, whether that's the needle, the refrigeration, the travel hassle, or the cost. Until recently the realistic choices were to stay on the shot, step down to a lower dose, or stop. A randomized trial published in 2026 tested a fourth option: switching to a daily GLP-1 pill.
This guide covers what that trial found, how it compares with your other options, and what it left unanswered.
The short version
In the one trial so far, people who switched from injectable tirzepatide or semaglutide to the daily pill orforglipron kept most of their weight loss over the following year. People switched to a placebo pill kept far less, and most of them needed to be put back on active medication.
The catch is that the trial compared the pill against stopping. It did not compare the pill against staying on the injection. So it shows that switching beats quitting. It can't tell you how switching compares with carrying on as you are.
What the pill is
Orforglipron is a once-daily GLP-1 pill made by Eli Lilly and sold in the US as Foundayo. The FDA approved it for weight management on April 1, 2026. Unlike oral semaglutide, it can be taken at any time of day without food or water restrictions.
It is a less powerful weight-loss drug than the injections. According to PubMed, in its main trial the highest dose produced an average 11.2% weight loss over 72 weeks (Wharton et al., The New England Journal of Medicine, 2025, DOI). In a head-to-head trial, injectable tirzepatide produced 20.2% and injectable semaglutide 13.7% over the same period (Aronne et al., , 2025, ).
Can I switch from Zepbound or Wegovy to a pill and keep the weight off?
One randomized trial says mostly yes. In ATTAIN-MAINTAIN, people who switched from injectable tirzepatide to the daily pill orforglipron kept about 75% of their weight loss after a year, and people who switched from injectable semaglutide kept about 79%. People switched to a placebo pill kept about 49% and 38%. The trial did not compare the pill with staying on the injection, so it shows that switching beats stopping, not that it matches continuing.
Will I regain weight if I switch from tirzepatide to a GLP-1 pill?
On average, some. In the trial, people coming off tirzepatide had lost 21.5% of their starting weight and finished the year on the pill 16.8% below it, an average regain of about 5 kg (11 lb). People coming off semaglutide regained about 1 kg. The authors think the difference is because tirzepatide acts on two hormone pathways and orforglipron on one, so it's a bigger step down.
Is the GLP-1 pill as strong as the injections?
No. In its main trial the highest orforglipron dose produced an average 11.2% weight loss over 72 weeks, compared with 20.2% for injectable tirzepatide and 13.7% for injectable semaglutide in a head-to-head trial. The maintenance trial tested a different question: whether a weaker drug can hold on to a loss that a stronger one produced. For most people in that trial, it largely did.
Do I have to start the pill at the lowest dose when switching from an injection?
In the trial, no. People moved straight from their injection to a mid-range dose of orforglipron, skipping the lowest starting doses. About 1 in 10 reported nausea, vomiting, or diarrhea in the first four weeks, mostly mild to moderate, and nobody needed a dose reduction in that period. Your prescriber decides your starting dose, so ask whether they'd follow the trial's approach.
Evidence: For & Against
Both sides of the topic, so you can weigh the evidence yourself.
4Supporting
Revision history
Last updated · 4 revisions recorded.
Show what changed
v4
Published
v3
Common questions 0 → 7
v2
Evidence sources 0 → 8
v1
Created
Improve this page▾
Community notes
Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.
Loading notes…
New submissions are currently paused. Existing approved notes remain available.
That gap matters for what follows. A drug doesn't need to be strong enough to produce a 20% loss in order to help you keep most of one. That is the idea the maintenance trial set out to test.
What the trial did
According to PubMed, ATTAIN-MAINTAIN enrolled 376 adults at 29 US sites (Aronne et al., Nature Medicine, 2026, DOI ↗ (external link)). All of them had just finished 72 weeks on the highest dose they could tolerate of either injectable tirzepatide or injectable semaglutide in an earlier trial. None had type 2 diabetes.
They were then randomly assigned to a daily orforglipron pill or an identical placebo pill for 52 weeks. Neither they nor their doctors knew which they were taking. Everyone received healthy-lifestyle counseling throughout.
From week 24 onward, anyone who had regained half or more of their lost weight was given real orforglipron as a rescue. That was the ethical choice, and it also shapes how the results should be read (more on that below).
What it found
If you were coming off tirzepatide (205 people):
People on the pill kept about 75% of their weight loss. People on placebo kept about 49%.
About 44% of the pill group held on to at least four-fifths of their loss, against about 16% on placebo.
In practical terms, the pill group had lost 21.5% of their starting weight on the injection and finished the year 16.8% below it. That's an average regain of about 5 kg (11 lb).
If you were coming off semaglutide (171 people):
People on the pill kept about 79% of their weight loss. People on placebo kept about 38%.
About 55% of the pill group held on to at least four-fifths of their loss, against about 7% on placebo.
The pill group had lost 16.5% on the injection and finished the year 15.1% below their starting weight. That's an average regain of about 1 kg (2 lb).
Blood sugar, blood pressure, waist size, and cholesterol improvements were largely preserved in both pill groups.
Why the tirzepatide group regained more
The trial authors expected this. Tirzepatide acts on two hormone pathways (GIP and GLP-1), and orforglipron acts on one. Moving from a stronger two-pathway drug to a single-pathway pill is a bigger step down than moving between two GLP-1 drugs. The authors say this explanation still needs further study.
If you're on Zepbound or Mounjaro, the realistic expectation from this trial is that you'd keep most of your loss but give some back. If you're on Wegovy or Ozempic, the trial suggests you might give back very little.
What the switch felt like
One worry about switching is whether you'd have to start the pill at the bottom and climb the dose ladder again, with a fresh round of nausea. The trial tested a shortcut: people went straight from their injection to a mid-range dose of orforglipron, skipping the lowest starting doses.
It went reasonably well. In the first four weeks, about 1 in 10 people reported nausea, vomiting, or diarrhea, most of it mild to moderate. Nobody needed their dose reduced during that period. Over the full year, between 4.8% and 7.3% of people on the pill stopped it because of side effects.
There was one confirmed case of mild pancreatitis in the pill group, and a small number of people in both the pill and placebo groups had raised liver enzymes. The authors reported no liver safety signal overall.
What the trial can't tell you
These limits come from the paper itself, and they're significant.
There was no "stay on the injection" group. This is the biggest one. The trial shows that switching to the pill beats switching to nothing. It doesn't show how switching compares with simply continuing your current injection, which in other trials has held or even extended weight loss.
It ran for one year. Nobody knows yet whether the pill holds weight in year two or three.
Rescue treatment blurs the placebo comparison. Because people on placebo who regained heavily were moved onto real medication, the placebo group's final numbers look better than true stopping would. By the end, only about 31% of the placebo group coming off tirzepatide, and 18% coming off semaglutide, had made it through without active medication.
The population was narrow. All US sites, predominantly white, no type 2 diabetes.
The manufacturer ran it. Eli Lilly funded the trial, and 8 of the 14 authors are Lilly employees. That's normal for a trial of this kind, and the design was randomized and double-blind, but it's worth knowing when the company also sells the pill.
It's one trial. The authors call it the first of its kind. Nothing has replicated it yet.
How this fits with your other options
If you've reached a weight you're happy with, you now have more paths than "stay or stop." Here is how the evidence for each compares.
Option
What the evidence shows
Stay on your current injection
Strongest evidence for keeping, and sometimes extending, your results.
Step down to a lower injection dose
One randomized trial. People who dropped to tirzepatide 5 mg kept most of their loss, but about 1 in 4 regained half or more. See tapering vs. staying on a maintenance dose.
Switch to a daily pill
One randomized trial, covered here. Most of the loss kept, more so coming off semaglutide than tirzepatide. Not compared against staying on the injection.
Nobody has tested these options against each other. Choosing between a lower injection dose and a pill currently comes down to your preferences, your side effects, and what you can afford and access, more than to any head-to-head data.
Questions worth raising with your prescriber
Given which injection I'm on, how much regain should I realistically expect if I switch?
What would we treat as the signal to switch back? A specific number of pounds, or a percentage of what I lost?
Would I start the pill at a mid-range dose, as in the trial, or at the bottom?
What will the pill cost me compared with my injection, on my plan? Our guide to manufacturer savings cards covers the current Foundayo program.
Is a lower dose of my current injection a better fit for me than switching drugs?
The bottom line
A daily pill is now a tested way to hold on to weight lost with an injection, and the one trial so far is encouraging: most people kept most of their loss, and the switch itself was tolerable. The result was stronger for people coming off semaglutide than off tirzepatide.
What the trial doesn't show is whether switching is as good as staying on your injection, or how it holds up past a year. If the injection is working and you can keep getting it, there's no evidence that switching improves anything. If you're going to come off the injection anyway, this trial suggests that moving to a pill is a much better plan than stopping outright.
Study findings above are attributed to their authors and were located via PubMed. This guide is general education and peer information, not medical advice. Decisions about switching or changing your medication belong with the prescriber who knows your history.
Is switching to a pill better than staying on my injection?
There's no evidence that it is. The trial had no group that stayed on the injection, and in earlier trials people who continued their injection didn't just hold their weight, they lost more. If your injection is working and you can keep getting it, nothing suggests switching improves your results. The pill is best understood as a much better option than stopping, for people who are coming off the injection anyway.
How long does the pill keep the weight off?
The trial ran for one year, so that's all anyone can say so far. Whether the pill holds weight in the second or third year hasn't been studied. It is also the first and only trial of its kind, run by the pill's manufacturer, so the findings haven't been independently repeated yet.
What is Foundayo?
Foundayo is Eli Lilly's brand name for orforglipron, a once-daily GLP-1 pill. The FDA approved it for weight management on April 1, 2026. Unlike oral semaglutide, it can be taken at any time of day without food or water restrictions.
Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found — STEP 1, SURMOUNT-4, SELECT, LEADER: GLP-1 trial names get quoted everywhere, usually without context. This reference page lists 205 named, completed GLP-1 trials in one place, grouped by drug and by question, with what each one tested, who sponsored it, its headline result, and a link to the published paper. It also lists the trials that finished but have not reported, and shows who paid for the research.
What the ADA guidelines say about GLP-1 medications — and what changed for type 1 diabetes in 2026 — The American Diabetes Association's Standards of Care is the reference most US clinicians follow, and it now puts GLP-1 medications at the center of treating diabetes with obesity. Here's what the guideline actually recommends — GLP-1s as the preferred obesity medication in type 2 diabetes, realistic weight-loss targets, the "highest dose isn't always the goal" point on dosing — plus the headline 2026 change: for the first time, the ADA cautiously supports GLP-1 therapy for people with type 1 diabetes and obesity, with important safety guardrails.
Stopping a GLP-1: tapering, weight regain, and restarting safely — Whether by choice or circumstance, most people stop a GLP-1 at some point. Here's what stopping can and can't get you, what withdrawal trials and real-world data show about weight regain and lost health benefits, whether a GLP-1 is really a medication for life, how tapering compares, and why restarting after a gap usually means re-titrating.
Common mistakes people make on GLP-1 medications — and how to avoid them — Most GLP-1 setbacks come from a short list of avoidable mistakes: treating it as a quick fix, neglecting protein and strength training, rushing the dose, under-hydrating, white-knuckling side effects, and going it alone. Here's the rundown of the most common ones, why they matter, and where to find the fix for each.
GLP-1 microdosing: what it means, why people do it, and what the evidence actually says — "Microdosing" GLP-1s is all over social media — using much smaller doses than the label calls for, for weight maintenance, side-effect avoidance, cost, or vague wellness claims. Here's what the term actually means, the kernel of real medicine it borrows from, why no clinical trial has tested it, the specific risks of the DIY version, and the legitimate way to have a lower-dose conversation with your prescriber.